362 related articles for article (PubMed ID: 27512204)
1. Treatment of Chronic Spontaneous Urticaria with a Single Dose of Omalizumab: A Study of Four Cases.
Subramaniyan R; Chopra A
Indian J Dermatol; 2016; 61(4):467. PubMed ID: 27512204
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
Finlay AY; Kaplan AP; Beck LA; Antonova EN; Balp MM; Zazzali J; Khalil S; Maurer M
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1715-1721. PubMed ID: 28573683
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
Carrillo DC; Borges MS; García E; Egea E; Serrano CD
World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies.
Mandel VD; Guanti MB; Liberati S; Demonte A; Pellacani G; Pepe P
Dermatol Ther (Heidelb); 2018 Jun; 8(2):291-301. PubMed ID: 29770909
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
9. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
12. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
15. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
17. Long-term management of chronic spontaneous urticaria with omalizumab.
Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
